Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serlopitant for Refractory Chronic Cough
2017-003250-16Phase 2Completed
- Sponsor
- Menlo Therapeutics Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in refractory chronic cough (RCC) comparing Serlopitant with Placebo (2 arms). Primary endpoint: Change from Baseline in 24-hour Cough Frequency at Week 12. Started Nov 2017; status: completed.
02
Drugs
serlopitant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on 2017-003250-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003250-16.